Scott M. Rocklage, PhD
Scott M. Rocklage, Ph.D. joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004. Dr. Rocklage has over three decades of healthcare management experience with strategic leadership responsibilities that led to FDA approval of three U.S. New Drug Applications (Omniscan™, Teslascan® and Cubicin®). Dr. Rocklage has served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar and has also held R&D positions at Salutar and Catalytica. Dr. Rocklage formerly served as Board Chairman of Relypsa (NASDAQ: RLYP) and Novira (acquired by J&J). He currently serves as Board Chairman of Rennovia, Kinestral and Cidara (NASDAQ: CDTX) as well as on the Boards of Epirus (NASDAQ: EPRS) and Pulmatrix (NASDAQ: PULM). Dr. Rocklage was formerly Executive Chairman of Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed) and Semprus (acquired by Teleflex). Dr. Rocklage received his B.S. in Chemistry from the University of California, Berkeley and his Ph.D. in Chemistry from MIT where he conducted research in the laboratory of Richard R. Schrock (Nobel Prize in Chemistry in 2005). He is an inventor or co-inventor of over 30 U.S. patents and has more than 100 peer-reviewed publications. Dr. Rocklage is based in the Boston, MA office.
Christian S. Schade
President and Chief Executive Officer
Mr. Schade has more than 30 years of private and public pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in the investment banking industry. Prior to joining Aprea Therapeutics, he was Chief Executive Officer of Novira Therapeutics, which was acquired in December 2015 by Johnson & Johnson in an all-cash transaction. Prior to joining Novira, Mr. Schade was Executive Vice President and Chief Financial Officer at Omthera, a NASDAQ-listed specialty pharmaceuticals company focused on the development and commercialization of new therapies for dyslipidemia. At Omthera, Mr. Schade was responsible for all corporate finance, accounting and business development activities, and led the sale of Omthera in July 2013 to AstraZeneca. He also was Executive Vice President and Chief Financial Officer at NYSE-listed NRG Energy, and from 2000 to 2009, he was Senior Vice President of Administration and Chief Financial Officer at Medarex, a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders and infectious diseases. Mr. Schade played a pivotal role in the acquisition of Medarex by Bristol-Myers Squibb, leading the negotiations for the sale and the eventual merger-integration process of the research, development and administrative functions. Before joining Medarex, Mr. Schade served as Managing Director at Merrill Lynch in London and held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade received an MBA from the Wharton School at the University of Pennsylvania and an AB from Princeton University. Mr. Schade currently serves on the Board of Directors of Integra Life Sciences Inc. and the Board of Directors of Indivior PLC.
Guido Magni, MD, PhD
Dr. Guido Magni is a Partner with Versant Ventures. Guido previously served as a Managing Director of EuroVentures, a Versant incubator, where he was intimately involved in several biotech investments including Synosia (sold to Biotie Therapies), Flexion and Okairos. Guido was previously the Global Head of the Medical Science Department of Roche Pharmaceuticals in Basel, Switzerland. During his twelve-year term at Roche, Guido oversaw the development and the registration of a large number of new chemical and biological entities including Cellcept, Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva. Currently, Guido serves on the Board of Biotie and AM Pharma, with previous board positions at Adolor Corporation and Anabasis Pharma before their recent acquisitions. Guido was trained at the University of Padua with a specialization in neuro-psychiatry. He is the co-author of over 100 peer-reviewed papers.
Johan Christenson, MD, PhD
Dr. Christenson is a Partner of HealthCap. Prior to joining HealthCap in 2001, Dr. Christenson was with SEB Företagsinvest (the venture capital arm of SEB) to supervise its health care portfolio. He has senior management experience from Astra Pain Control as Project director and AstraZeneca as Global Product Director and member of the global therapy area management team of Pain & Inflammation. Dr. Christenson received his medical training at the Karolinska Institute and received his PhD in basic neuroscience in 1991. He served as a lecturer in neuroscience and also held a position as Assistant Dean at the Karolinska Institute Graduate School for two years. Dr. Christenson has four years of clinical specialist training in paediatrics and paediatric neurology.
Jonathan Hepple, PhD
Dr. Jonathan Hepple represents Rosetta Capital Ltd. where he is one of the founding Partners. Jonathan has over 17 years of investment experience in the life sciences, initially at Rothschild Asset Management and then as co-founder of BioScience Managers Ltd. Jonathan currently serves as a Director on the Board of a number of private life science companies including NovImmune, Procertus and Clanotech. He was previously a Director of Covagen AG and Opsona Therapeutics. He received his PhD from Cambridge University for cancer research.
Bernd R. Seizinger, MD, PhD
Dr. Bernd R. Seizinger, M.D., Ph.D. is currently Chairman and/or Board member of a number of private and public biotech companies in the U.S., Canada and Europe, including: Oxford BioTherapeutics Ltd., CryptoMedix Inc., Aprea AB, Vaccibody AS, and BioInvent AB and Oncolytics Inc. From 1998 to 2009, he served as President and Chief Executive Officer of GPC Biotech. He was also Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances at Bristol-Myers Squibb in Princeton, NJ. Prior to his appointments in the biotechnology and pharmaceuticals sectors, Dr. Seizinger held professorships and senior staff appointments at Harvard Medical School, Princeton University and Massachusetts General Hospital.